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ABSTRACT We have localized a region contained within the sequence of amino acid residues 4425–4621 on the three-
dimensional structure of the skeletal muscle ryanodine receptor (RyR). Mouse monoclonal antibodies raised against a peptide
comprising these residues have been complexed with ryanodine receptors and imaged in the frozen-hydrated state by
cryoelectron microscopy. These images, along with images of antibody-free ryanodine receptor, were used to compute
two-dimensional averaged images and three-dimensional reconstructions. Two-dimensional averages of immunocomplexes
in which the ryanodine receptor was in the fourfold symmetrical orientation disclosed four symmetrical regions of density
located on the edges of the receptor’s cytoplasmic assembly that were absent from control averages of receptor without
added antibody. Three-dimensional reconstructions revealed the antibody-binding sites to be on the so-called handle
domains of the ryanodine receptor’s cytoplasmic assembly, near their junction with the transmembrane assembly. This study
is the first to demonstrate epitope mapping on the three-dimensional structure of the ryanodine receptor.
INTRODUCTION
Ryanodine receptors (RyRs) are the major calcium release
channels in striated muscle (for reviews see Fleischer and
Inui, 1989; Meissner, 1994; Ogawa, 1994; Coronado et al.,
1994; Franzini-Armstrong and Protasi, 1997; Wagenknecht
and Radermacher, 1997; Shoshan-Barmatz and Ashley,
1998). They are the largest ion channels known, having net
molecular masses of 2.3 MDa. The purified, detergent-
solubilized skeletal receptor is composed of four identical
copies of a large subunit (Mr 565 kDa) that are responsible
for ion conduction and most of the receptor’s pharmacolog-
ical properties. Up to four copies of a small modulatory
protein, identified as FKBP12, a 12-kDa FK506-binding
protein, bind with nanomolar affinity to the receptor and
copurify with it (Jayaraman et al., 1992). RyRs receive a
signal upon depolarization of the transverse tubule that
stimulates them to release calcium from the lumen of the
sarcoplasmic reticulum (SR) into the myoplasm. The Ca2
binds to the myofibrils, resulting in contraction of the mus-
cle. Ligands such as Ca2, Mg2, ATP, calmodulin, and
FKBP12 are known to bind to the isolated RyR and to
modulate its activity (Liu et al., 1989; Smith et al., 1988;
Jayaraman et al., 1992; Timerman et al., 1993; Tripathy et
al., 1995).
Several laboratories, including our own, have determined
three-dimensional reconstructions of RyR from skeletal
muscle (RyR) to 3-nm resolution from electron micro-
graphs of negatively stained or frozen-hydrated, detergent-
solubilized receptors (Wagenknecht et al., 1989, 1997; Ra-
dermacher et al., 1994; Wagenknecht and Radermacher,
1995; Serysheva et al., 1995; Orlova et al., 1996; Samso´ and
Wagenknecht, 1998). Unfortunately, correlation of the
three-dimensional architecture of RyR with the sequence of
its major subunit has been limited. To begin addressing this
problem, we describe here the first reconstruction of RyR
complexed with sequence-specific antibodies.
A region of the RyR sequence, residues 4425–4621, has
been implicated in the calcium-dependent regulation of ion
channel activity by directly binding Ca2 and through in-
teraction with Ca2-calmodulin (Zorzato et al., 1989; Fill et
al., 1991; Treves et al., 1993; Menegazzi et al., 1994; Chen
et al., 1992, 1993). These regulatory sites lie in the amino-
terminal half of the fusion peptide, and in the native recep-
tors are likely located in its cytoplasmic domains. The
sequence 4425–4621 is also thought to contain one of the
RyR’s transmembrane segments, residues 4554–4575.
Here we have applied cyromicroscopy and image recon-
struction techniques to immunocomplexes of RyR and a
monoclonal antibody specific for residues 4425–4621 to
map the location of this region of the RyR sequence on the
three-dimensional architecture of the receptor. We find that
there are four symmetrically positioned binding sites for the
antibody located on the edges of the cytoplasmic assembly of
the receptor, near its junction with the transmembrane region.
MATERIALS AND METHODS
Materials
The antibodies, raised against a fusion peptide corresponding to residues
4425–4621 of RyR, were prepared as described previously (Larini et al.,
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1995), after immunization of Balb/c mice with fusion protein PC15 (Treves
et al., 1993). The subclass of the monoclonal antibody was determined to
be IgG1 with a mouse monoclonal antibody isotyping kit (catalog no.
ISO-1; Sigma Immunochemicals, St. Louis, MO). For cryoelectron mi-
croscopy the antibody was concentrated approximately ninefold by ultra-
filtration (Centricon 30 device; Amicon) after dialysis into a buffer con-
sisting of 20 mM Tris-HCl (pH 7.5), 0.5 M KCl, 0.5 g/ml leupeptin, and
2 mM dithiothreitol.
3-((Cholamidopropyl)dimethylammonio)-1-propane sulfate (CHAPS)
was obtained from Calbiochem (La Jolla, CA). [3H]Ryanodine (61.0 Ci/
mmol) was from New England Nuclear. All other reagents were obtained
from Sigma.
Rabbit RyRs were isolated from terminal cisternae vesicles of the SR
(Saito et al., 1984) after solubilization in the presence of 4% CHAPS (Inui
et al., 1987). The solubilized receptor was purified as previously described
(Wagenknecht et al., 1997; Lai et al., 1988).
Western blot of terminal cisternae and bacterial
cell extracts and immunoblotting using mAbI-29
DNA manipulations were carried out according to standard protocols as
described by Maniatis et al. (1989). To cover the entire RyR coding
sequence, we constructed a panel of RyR fusion proteins as previously
described (Treves et al., 1993; Zorzato et al., 1996).
Competitive ELISA assay
The procedure was adapted from Grunwald and Meissner (1995). Micro-
titer plate wells (Corning polystyrene) were coated with purified RyR by
drying 0.3 g of receptor (0.5 pmol RyR subunit) from deionized water
followed by fixation with 10% methanol. The wells were rinsed three times
with TBS-T (Tris-buffered saline, 0.05% Tween-20), blocked by incuba-
tion with 5% dry milk in TBS overnight at 4°C, and washed again three
times with TBS-T. Antibody mAbI29 (monoclonal mouse antibody raised
against a peptide corresponding to residues 4425–4621 of the ryanodine
receptor) (at 0.5 or 1.0 g/ml) was incubated overnight at 4°C with RyRs
(at 0, 0.2, 1.0, 2.0, and 10 g/ml) in buffer containing 22.5 mM Na-3-(N-
morpholino)propanesulfonic acid (pH 7.4), 0.15 M NaCl, 0.06 mM dithio-
threitol, 0.05% CHAPS, 2.5 g/ml leupeptin, and 1% nonfat dry milk. To
each RyR-coated well was added 0.1 ml of one of the RyR-antibody
mixtures, followed by 2 h of incubation at room temperature. The wells
were washed and the amount of plate-bound antibody was quantified by the
addition of IgG-alkaline phosphatase-labeled secondary antibody followed
by color development with p-nitrophenyl phosphate, as recommended by
the manufacturer (Sigma).
Immunoprecipitation of solubilized RyR by
mAbI29 detected by radioassay
Purified RyR (0.45 g) was incubated for 1 h at 23°C with mAbI29
included at 0.5, 1.0, 2.0, and 4.0-fold molar excess over RyR subunits in 65
l of calcium-buffer F (final concentration: 20 mM Tris-Cl (pH 7.4), 0.5
M KCl, 2 mM dithiothreitol, 1 g/ml leupeptin, 100 M CaCl2, and 1%
(v/v) of [3H]ryanodine at 12 nM (8.62 Ci/ml)). In the control reaction,
rabbit IgG was substituted for mAbI29. Used as a secondary antibody,
rabbit anti-mouse IgG at a concentration of 45 g/ml was incubated with
the immune complexes for 30 min at 4°C. Immune complexes were
precipitated using 40 l of a 50% (v/v) slurry of protein A-agarose
(equilibrated versus calcium buffer F less ryanodine) incubated at 4°C for
1 h with agitation. The reaction supernatant was recovered, subjected to
PEG precipitation (Shoshan-Barmatz and Zarka, 1992), and filtered
through Whatman GF/B filters for detection of nonprecipitated protein-
bound radioactivity. Each agarose pellet was washed three times with 400
l of calcium buffer F less ryanodine. Recovered pellets were shaken in 10
ml of liquid scintillation cocktail and counted with a Beckman LS 9000
counter. Radioactivity of wash supernatants (100 l) was also monitored.
Cryoelectron microscopy and image processing
Immunocomplexes were prepared by diluting RyRs 10-fold into concen-
trated mAbI29 such that the final protein concentrations were 0.05 mg/ml
for RyR and 0.675 mg/ml for mAbI29 (molar ratio  50:1). The final
buffer concentrations were 0.5 g/ml leupeptin and 0.05% CHAPS. Con-
trol RyR was prepared identically, except that antibody was omitted. The
reaction was incubated at room temperature for 15 min, and then 5-l
aliquots were applied to carbon-coated electron microscope grids and
frozen (Radermacher et al., 1992, 1994). The grids were transferred to a
Gatan model 626 cryoholder and analyzed by electron microscopy, using
a Philips EM420 transmission electron microscope operated at 100 kV and
a magnification of 52,000 (Wagenknecht et al., 1994). Untilted cryogrids
were used to collect images for two-dimensional averaging of receptors in
the fourfold symmetrical orientation, the most frequently occurring view.
Images used for three-dimensional reconstructions were obtained from
untilted cryogrids and from grids tilted by 30° in the microscope so as to
increase the sampling of orientations.
Using the SPIDER software package (Frank, 1996), image processing
was done as previously described (Wagenknecht et al., 1994; Sharma et al.,
1998).
Two-dimensional averaged images of RyR and RyR:mAbI29 were
computed using a homogenous data set of aligned fourfold symmetrical
RyR images that had been classified by multivariate statistical analysis as
previously described (Radermacher et al., 1994). The averaged RyR image
was subtracted from that of RyR:mAbI29. Differences were considered
statistically significant if they exceeded the standard error of the mean by
a factor of 3, which corresponds to a significance level greater than 98%
(Frank, 1996).
Three-dimensional reconstructions were determined using a projection
matching technique (Penczek et al., 1994). In this technique a preexisting,
three-dimensionally reconstructed RyR (Radermacher et al., 1994) was
projected in a series of evenly spaced orientations. The RyR-mAbI29
images were individually matched to one of these projections and assigned
the corresponding Eulerian angles for that projection. A three-dimensional
reconstruction was then generated using these assigned angles. This pro-
cedure was iterated five times, using the reconstruction from the previous
iteration to minimize the bias from the preexisting reconstruction used. The
RyRs (without antibody) were processed independently by the same pro-
cedure to generate the control three-dimensional reconstruction. The res-
olution for three-dimensional (3D) reconstructions was determined using
Fourier shell correlation with a cutoff value of 0.5 (Bottcher et al., 1997).
Differences between reconstructions containing bound antibody and con-
trol reconstructions lacking antibody were analyzed in the same manner as
other, previously characterized RyR-ligand complexes (Wagenknecht et
al., 1997; Samso´ et al., 1999).
RESULTS AND DISCUSSION
Characterization of mAbI29 specificity
We produced a monoclonal antibody against a fusion pro-
tein covering a region encompassed by residues 4425–
4621, which have been demonstrated previously to be in-
volved in the regulation of the RyR (Treves et al., 1993;
Menegazzi et al., 1994). Lane 1 of Fig. 1 B shows that
mAbI29 reacts strongly with the RyR present in the terminal
cisternae fraction. To demonstrate that mAbI29 reacts with
the epitope contained in the polypeptide defined by residues
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FIGURE 1 Western blot of terminal cisternae and bacterial cell extracts and immunoblotting characterization of mAbI29. The top line indicates the
full-length rabbit RyR cDNA, and the segments below indicate the sizes of the RyR cDNA fragments cloned into the pATH bacterial expression vector
(Menegazzi et al., 1994). Proteins in rabbit skeletal muscle terminal cisternae and bacterial cell extracts were electrophoretically separated by polyacryl-
amide gel electrophoresis in the presence of sodium dodecyl sulfate, transferred onto nitrocellulose filters, and reversibly stained with (A) Ponceau red and
(B) indirect immunoenzymatic staining with mAbI29 (final concentration 1 g/ml). Lane 1: 20 g terminal cisternae; 20–50 l of E. coli JM101 extracts
were loaded on the gel. Lane 2: Extract from induced E. coli culture transfected with the pATH vector only. Lanes 3–13: E. coli extracts from induced
culture with pATH RyR constructs; white dots indicate the fusion proteins in the extracts. Lane 3: PC10; lane 4: PC1; lane 5: PC3; lane 6: PC21; lane
7: PC22; lane 8: PC28; lane 9: PC29; lane 10: PC6; lane 11: PC15; lane 12: PC14; lane 13: PC9.
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4425–4621, we probed it against a panel of fusion proteins
covering the entire coding sequence of the RyR (Fig. 1 A).
As expected, mAbI29 reacted only with its antigen (fusion
protein PC15; Fig. 1 B, lane 11). mAbI29 did not recognize
either the trpe bacterial protein (Fig. 1 B, lane 2), which was
common to all of the fusion proteins, or any of the other
RyR fusion proteins.
Before attempting to prepare immunocomplexes for cryo-
microscopy, we tested the murine antibody mAbI29 for
binding to the purified, detergent-solubilized RyR. A com-
petitive enzyme-linked immunosorbent assay (ELISA) was
performed in which mixtures of mAbI29 and solubilized
RyR were incubated and then added to microtiter plate wells
containing immobilized RyR. The amount of antibody
bound to immobilized RyR was quantified by a colorimetric
assay employing alkaline phosphatase-labeled secondary
antibody (see Materials and Methods). The solubilized RyR
was found to be an effective inhibitor of antibody binding to
the immobilized receptor (Fig. 2 A).
To estimate the concentration of precipitating antibody,
we performed immunoprecipitation experiments in which
solubilized, [3H]ryanodine-labeled RyR at the same concen-
tration as would be used for cryoelectron microscopy was
titrated with antibody. From the binding curve (Fig. 2 B), it
was apparent that, at the highest antibody concentration,
saturation of binding was not achieved. We concluded that
it would be necessary to further concentrate the antibody to
achieve the near-stoichiometric levels of binding that would
be required for detection of RyR-bound antibody by cryo-
electron microscopy. Ultrafiltration was used to concentrate
the antibody solution approximately ninefold. Because of
the limited amounts of antibody available, the concentrated
material was used for microscopy without further charac-
terization, except for gel electrophoresis to verify that the
antibody was successfully concentrated (data not shown).
Cryoelectron microscopy and two-dimensional
image analysis of RyR:mAbI29 complexes
Isolated RyR was incubated with and without (control)
concentrated mAbI29, and aliquots of the reactions were
applied to grids for cryo-EM (see Materials and Methods).
For two-dimensional analysis, electron microscopy data
were collected from nontilted specimen grids to maximize
the number of fourfold symmetrical orientations. RyRs tend
to adhere in orientations such that their fourfold symmetry
axes are normal to the supporting carbon film. Fig. 3 A
shows a selected area of an electron micrograph of isolated
RyR, and Fig. 3 B shows a field of RyR:mAbI29 complexes
(arrows 1–3 indicate a few of the RyRs in fourfold orien-
tations). The micrographs of RyR:mAbI29 differ from those
of RyR alone in two ways. First, they contain substantial
amounts of nonreceptor protein in the background, which is
most likely due to the presence of protein that was not
bound to the RyRs. Second, many of the RyRs appeared to
be aggregated, probably as a result of interreceptor cross-
linking by the antibodies. Efforts were made to isolate the
ryanodine receptor-mAbI29 complex from the unbound an-
tibodies by size exclusion chromatography and ultrafiltra-
tion, but electron microscopy showed that this treatment
apparently damaged the RyRs. Despite the excess protein
that was present in the RyR:mAbI29 mixture, a sufficient
number of isolated, morphologically intact RyRs were eas-
ily identified in the micrographs.
Fig. 4, A and B, shows averages of fourfold symmetrized
RyR:mAbI29 and RyR complexes, respectively. Fig. 4 C
shows a difference map obtained after the averaged image
of RyR was subtracted from that of RyR:mAbI29. Light
(white) regions indicate mass present in the RyR-mAbI29
FIGURE 2 Characterization of antibody mAbI29 binding to RyR. (A)
Competitive ELISA. RyRs were immobilized on microtiter plate wells and
probed with mAbI29 (at concentrations of 0.5 and 1.0 g/ml) containing
solubilized RyR at the levels indicated on the abscissa. (B) A partial
binding curve obtained by immunoprecipitation of [3H]ryanodine-labeled
RyR with increasing amounts of antibody mAbI29. Nonspecific rabbit IgG
failed to precipitate significant amounts of RyR.
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complex that is absent from RyR. As seen in Fig. 4 C, four
symmetrically disposed regions dominate the difference im-
age. The density associated with these differences is more
than twice that of any other positive differences. A statisti-
cal analysis (see Materials and Methods) of the difference
image indicates that these four regions are significant with
a confidence level greater than 98% (Fig. 4 D). We attribute
these highly significant and localized regions of difference
to the excess mass contributed by mAbI29 and consider
them to be indicative of the location of an epitope contained
within amino acid residues 4425–4621, to which the anti-
body was raised.
FIGURE 3 Cryoelectron microscopy
of RyR and RyR:mAbI29: portions of
micrographs of (A) isolated RyR and
(B) RyR:mAbI29 complexes. Arrows
1, 2, and 3 mark ryanodine receptors in
the fourfold symmetrical orientation
used for two-dimensional averaging.
Arrows 4, 5, and 6 denote ryanodine
receptors in nonfourfold orientations,
which are required for three-dimen-
sional reconstruction. Scale bar, 700 Å.
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Three-dimensional reconstruction of
RyR:mAbI29 complexes
The image obtained by averaging RyR:mAbI29 complexes
in the fourfold-symmetrical orientation does not define the
location of the bound antibody in the direction parallel to
the axis of symmetry (which we define as the z direction),
and therefore, 3D reconstructions were determined for con-
trol and RyR:mAbI29 immunocomplexes. To obtain a suf-
ficient number of non-fourfold-symmetrical views (e.g.,
Fig. 3, arrows 4–6), which are essential for 3D reconstruc-
tion, micrographs were recorded with the specimen grids
tilted by 30°. The individual images were extracted from the
micrographs and used to compute a 3D reconstruction (see
Materials and Methods).
Representations of the 3D reconstructions obtained for
RyR without added antibody and for RyR:mAbI29 are
similar when displayed as solid bodies, and by examination
it is not obvious where the mass contributed by bound
antibody is located (Fig. 5, A and B). The reconstructions
show that the RyR comprises two main components, a
transmembrane region or assembly (labeled TA) and a
larger cytoplasmic assembly containing at least 10 distinct
domains (labeled 1–10), each present four times, as dictated
by the quaternary structure of the receptor. These features
are essentially identical to results of prior reconstructions
from our laboratory (Radermacher et al., 1994; Wagen-
knecht et al., 1997). Reconstructions determined under
these conditions resemble those of the “closed” state of the
receptor described previously (Orlova et al., 1996) and
confirmed in our own laboratory (Sharma and Wagen-
knecht, unpublished results). Several structural features ap-
pear slightly enlarged in the RyR:mAbI29 reconstruction
relative to the RyR reconstruction—for example, the trans-
membrane assembly and domains 3, 6, and 10 in the cyto-
plasmic region. These differences in overall shape probably
are not attributable to changes induced by binding of anti-
bodies in a specific manner, but more likely arise from the
large amount of excess protein that was present in the
solution of antibody that was added to the receptor (Fig. 3),
some of which might have interacted nonspecifically with
the receptor. Subtraction of the two reconstructions was
necessary to determine the areas of greatest, and presumably
most significant, localized differences in density between
the two reconstructions. Fig. 5 C shows the reconstruction
of RyR without added antibody together with the largest
differences attributed to bound mAbI29 superimposed (pur-
ple regions). The regions of greatest difference are associ-
ated with the domains labeled 3, also referred to as the
“handles” (Orlova et al., 1996). When the 3D difference
map is projected in the z direction, the differences associ-
FIGURE 4 Two-dimensional im-
age averaging of RyR:mAbI29 and
RyR. (A) Average of RyR:mAbI29
complex (N  119). (B) Average of
RyR (N  234). (C) Difference map
with contours superimposed, formed
by subtracting the two-dimensional
reconstruction in B from that in A.
Note that the four symmetrically dis-
posed regions of highest difference
are more than twice as large as any
other differences. (D) The most sig-
nificant statistical differences (98%
significance level) in C, determined
as described in Materials and Meth-
ods (white regions). Scale bar, 150 Å.
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ated with the handles lie at the same locations as the major
differences that were observed in the two-dimensional av-
eraged images. This agreement of the two- and three-di-
mensional analyses is further evidence that these regions of
excess density are highly significant because there is little
overlap between the two data sets. Thus the main density
differences that are associated with the handles represent the
most likely locations for the epitope that is recognized by
mAbI29.
The density attributed to bound antibody in the recon-
struction of RyR:mAbI29 is weaker and more diffuse than
might be expected based solely upon the resolution of the
reconstruction, estimated at 34 Å. It is not unusual in studies
of this type for only the Fab portion of the antibody that is
binding to the substrate to be clearly resolved. When the
antibody binds to the RyR, the distal portion of the antibody
is quite flexible and assumes many different positions, re-
sulting in blurring. For the RyR:mAbI29 reconstruction
even the proximal Fab arm has not been fully resolved.
Other studies involving 3D reconstruction of immunocom-
plexes by electron microscopy have reported findings sim-
ilar to those described here, whereas in others the Fab
portion of the antibody has been resolved with sufficient
clarity to allow fitting of atomic models of Fab fragments
into the density envelope (for a recent discussion see Yu et
al., 1998). One possible explanation for less than optimal
visualization of mAbI29 in 3D reconstructions is that the
antibody was bound to a mobile region of the RyR, and
hence regions distal to its point of attachment were not as
well resolved as proximal regions. Indeed, potential un-
structured mobile segments, rich in the amino acids glycine,
alanine, and proline, are found within the RyR amino acid
sequence to which mAbI29 was raised (Treves et al., 1993).
Moreover, this sequence lies within a region (residues
4254–4631, which has been termed divergency region 1)
that varies more than any other among the three isoforms of
the ryanodine receptor (Sorrentino and Volpe, 1993). Fi-
nally, it is possible that the low density contributed by
bound antibody in the reconstructions was due to substoi-
chiometric occupancy of its epitopes on RyR due to partial
dissociation of antibodies that occurred upon adsorption to
the specimen grid.
Taking the preceding considerations into account, we
conclude that some portion of the sequence 4425–4621 is
contained within domain 3 (handle domain) of the RyR, at
a region that is proximal to the transmembrane assembly
FIGURE 5 Three-dimensional recon-
structions of RyR and RyR:mAbI29. (A)
Three-dimensional reconstruction of iso-
lated RyR (N  2852), showing cytoplas-
mic-facing (left), sarcoplasmic reticulum-
facing (middle), and side (right) views. (B)
Three-dimensional reconstruction of RyR-
mAbI29 (N  2065), shown in the same
orientations as in A. (C) As in A, except
that the differences (obtained by subtract-
ing the reconstruction in A from the recon-
struction in B) are superimposed. Shown is
the entire difference image obtained at the
chosen threshold, which was selected to
reveal the strongest differences. Scale bar,
150 Å.
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(see below). The three-dimensional analysis was repeated
with a different set of images to check experimental repro-
ducibility, with essentially identical results.
Comparison of experimental results with
previous studies
A location on domain 3 of the RyR for residues 4425–4621
seems reasonable when other information bearing on this
region of the sequence is considered. First, there is compel-
ling evidence that parts of this sequence are surface-exposed
and on the cytoplasmic side of the SR. The epitope recog-
nized by mAbI29 is readily accessible in vesicles derived
from terminal cisternae of skeletal-muscle SR. Polyclonal
antibodies raised to the peptide that was used to obtain
mAbI29 were found to influence in vitro the activity of the
channel in response to Ca2, implicating the sequence
4425–4621 in regulation of the RyR (Treves et al., 1993). In
addition to accessibility by mAbI29, the sequence 4425–
4621 contains sites at residues Lys4474 and Arg4475 that are
readily cleaved when proteases are added to isolated RyR or
RyR that is present in SR-derived vesicles (Marks et al.,
1990).
Besides surface-exposed residues, the sequence 4425–
4621 is thought to contain one of the transmembrane seg-
ments of the RyR; specifically, residues 4554–4575 are
among the most hydrophobic stretches found in the entire
RyR sequence, and experimental evidence that residues
adjoining the carboxy side of this sequence are located in
the lumen of the SR has been reported (Takeshima et al.,
1989; Zorzato et al., 1990; Grunwald and Meissner, 1995).
The preceding discussion, when combined with our 3D
localization of mAbI29 binding sites, suggests the following
model for the topology of the sequence 4425–4621 in the
RyR (Fig. 6). The antibody binding location found on
domain 3 of the 3D reconstruction (Fig. 5) probably corre-
sponds to the amino-terminal portion of the sequence 4425–
4621 (pink dot in Fig. 6), upstream of residues 4554–4575,
which form the putative transmembrane segment (zigzag
line in Fig. 6). The carboxy-terminal 46 residues (4576–
4621) are predicted to be located mostly in the lumen of the
SR (pink loop following the zigzag line in Fig. 6), according
to current models of the transmembrane topology of RyR
(Zorzato et al., 1990; Takeshima et al., 1989; Grunwald and
Meissner, 1995; Brandt et al., 1992). A bridge of density
spanning the region between domain 3 and the transmem-
brane assembly appears to connect the two regions.
At least six potential calmodulin-binding sites, widely
separated in the sequence of the RyR, have been proposed
based upon experiments involving calmodulin binding to
peptides derived from the RyR’s amino acid sequence
(Chen and MacLennan, 1994; Menegazzi et al., 1994; Guer-
rini et al., 1995). However, experimental support that cal-
modulin binds to any of these sequences in the native
receptor is lacking, and even the number of distinct cal-
modulin-binding sites on the intact receptor is uncertain
(Yang et al., 1994; Tripathy et al., 1995; Moore et al., 1999).
The bacterially expressed fusion protein, corresponding to
the RyR sequence 4425–4621, that was used as an antigen
to obtain mAbI29, is one of the peptides that has been
shown to bind calmodulin (Menegazzi it al., 1994). Thus it
is possible that the mAbI29-binding site that we have de-
termined in this study is at or near a calmodulin-binding site
on the RyR. In a previous study from this laboratory
(Wagenknecht et al., 1994, 1997), a RyR:calmodulin com-
plex was characterized by 3D reconstruction, and the cal-
modulin was found to bind in the crevice formed between
domain 3 and the “clamp” region that forms each of the
corners of the cytoplasmic assembly (indicated by the as-
terisk in Fig. 6). This site is clearly distinct from the
mAbI29-binding site found in this study. Based on our
model for the location and topology of the sequence corre-
sponding to RyR residues 4425–4461 (Fig. 6), it appears
unlikely that this sequence could extend to the calmodulin
site mapped previously. Thus, if the site defined by mAbI29
does indeed correspond to a calmodulin site, then it is a
different site from the one detected in our earlier study.
Further cryo-immuno-electron microscopic studies em-
ploying antibodies specific for other surface-exposed re-
gions of the RyR sequence should lead to a detailed model
for which segments of the sequence form the various do-
mains that comprise the receptor.
FIGURE 6 Model for topology of residues 4425–4621, superimposed
on the 3D model of RyR. This schematic model indicates the three-
dimensional location for sequence 4425–4621 of the skeletal muscle
ryanodine receptor. The dot indicates the antibody-binding region, which is
proposed to correspond to the amino-terminal region (indicated by N) of
the sequence. C denotes the carboxy-terminal portion of the sequence. The
asterisk indicates the CaM-binding site identified in previous studies (see
text).
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